Outcomes and inequalities in diabetes from 2004/2005 to 2011/2012: English longitudinal study

2004/2005 至 2011/2012 年糖尿病的结局和不平等现象:一项英国纵向研究

阅读:1

Abstract

BACKGROUND: Outcomes of diabetes care are unequal and the NHS has a duty to consider reducing inequality in healthcare outcomes. AIM: To quantify trends in socioeconomic inequality and diabetes outcomes. DESIGN AND SETTING: Whole-population longitudinal study of 32 482 neighbourhoods (Lower Layer Super Output Areas [LSOAs]) in England between 2004/2005 and 2011/2012. METHOD: Slope indices of inequality (SIIs) between neighbourhoods of great and little deprivation were measured annually for: glycated haemoglobin control in people with diabetes; emergency hospitalisation for diabetes; and amenable mortality from diabetes. RESULTS: From 2004/2005 to 2011/2012 glycaemic control improved in all social groups, regardless of deprivation level, although inequality was unchanged as measured by the SII (0.04, 95% confidence interval [CI] = -0.43 to 0.52). Diabetes-related amenable mortality improved in all social groups, but decreased at a faster rate in neighbourhoods of greater deprivation. Inequality in diabetes-related amenable mortality improved, with the SII falling by 2.68 (95% CI = 1.93 to 3.43), resulting in 594 (95% CI = 420 to 767) fewer deaths. In contrast, emergency hospitalisations for diabetes increased in all social groups, with faster growth in neighbourhoods of greater deprivation. The socioeconomic gradient increased with the SII widening by 19.59 admissions for diabetes per 100 000 (95% CI = 16.00 to 23.17), resulting in an increase of 5991 (95% CI = 5084 to 6899) excess admissions associated with socioeconomic inequality during the study period. CONCLUSION: In diabetes, mortality declined faster, but emergency hospitalisation grew faster in more deprived neighbourhoods. Unequal growth in emergency hospitalisation for diabetes is likely to be partly due to increased diabetes prevalence and patients living longer, but may also be due to overuse of glycaemic control medication.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。